Lung Cancer
Volume 68, Issue 1 , Pages 27-38 , April 2010

Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis

  • Hongqin Zhuang

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Weiwei Jiang

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Wei Cheng

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Kui Qian

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Wei Dong

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • Department of Chemistry, The School of Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210093, Jiangsu, PR China
    • ,
  • Lin Cao

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Qilai Huang

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Shufeng Li

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • College of Basic Medical Science, Southeast University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Fei Dou

      Affiliations

    • College of Basic Medical Science, Southeast University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Jen-Fu Chiu

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • Department of Anatomy, The University of Hong Kong, Hong Kong, China
    • ,
  • Xue-Xun Fang

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • Key Laboratory of Molecular Enzymology and Enzyme Engineering of Ministry Education, Jilin University, Changchun 130023, PR China
    • ,
  • Min Lu

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • ,
  • Zi-Chun Hua

      Affiliations

    • Jiangsu Center of Hepatobiliary Diseases, The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210093, Jiangsu, PR China
    • Changzhou High-Tech Research Institute of Nanjing University, Changzhou 213164, Jiangsu, PR China
    • Corresponding Author InformationCorresponding author at: The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, 22 Han Kou Road, Nanjing 210093, PR China. Tel.: +86 25 83593692; fax: +86 25 83324605.

Received 12 November 2008 ,Revised 30 March 2009 ,Accepted 9 May 2009.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA Cancer J. Clin. 2006;56:106–130
  2. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer. 2000;89:2334–2344
  3. Ferguson MK. Diagnosing and staging of non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 1990;4:1053–1068
  4. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 2001;299:31–38
  5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999;5:157–163
  6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999;104:155–162
  7. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 2004;64:4900–4905
  8. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 2003;63:4713–4723
  9. Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int. J. Oncol. 2004;24:1133–1140
  10. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003;2:1273–1284
  11. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42
  12. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 2000;10:369–377
  13. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818–821
  14. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66–75
  15. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 1998;16:395–419
  16. Colo GP, Rosato RR, Grant S, Costas MA. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett. 2007;581:5075–5081
  17. Ozoren N, El Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp. Cell Res. 2002;281:175–181
  18. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703
  19. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228–237
  20. Eid MA, Lewis RW, Abdel-Mageed AB, Kumar MV. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int. J. Oncol. 2002;21:111–117
  21. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia. 2003;17:1794–1805
  22. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 2004;23:4993–5003
  23. Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin. Cancer Res. 2001;7:3874–3883
  24. Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res. 2003;63:5118–5125
  25. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 1999;248:30–43
  26. Bostwick DG. Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol. Urol. 2000;4:101–106
  27. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000;60:7099–7105
  28. Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS, et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br. J. Cancer. 1998;77:1875–1879
  29. Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int. J. Cancer. 1999;84:234–238
  30. Malusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res. 2001;21:1015–1021
  31. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J. Cancer Res. Clin. Oncol. 2002;128:426–432
  32. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2000;2:645–652
  33. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318–1321
  34. Charette SJ, Lavoie JN, Lambert H, Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol. Cell Biol. 2000;20:7602–7612
  35. Concannon CG, Orrenius S, Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Exp. 2001;9:195–201
  36. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 1999;13:2061–2070
  37. Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, et al. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J. Biol. Chem. 2008;283:12305–12313
  38. Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene. 2000;19:1975–1981
  39. O’Callaghan-Sunol C, Gabai VL, Sherman MY. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 2007;67:11779–11788
  40. Venkatakrishnan CD, Dunsmore K, Wong H, Roy S, Sen CK, Wani A, et al. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest. Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1736–H1744
  41. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326
  42. Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13:239–252
  43. Beere HM, Green DR. Stress management—heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol. 2001;11:6–10
  44. Xanthoudakis S, Nicholson DW. Heat-shock proteins as death determinants. Nat. Cell Biol. 2000;2:E163–E165
  45. Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, Dawra R, et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 2007;67:616–625
  46. Conroy SE, Latchman DS. Do heat shock proteins have a role in breast cancer?. Br. J. Cancer. 1996;74:717–721
  47. Garrido C, Fromentin A, Bonnotte B, Favre N, Moutet M, Arrigo AP, et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 1998;58:5495–5499
  48. Morino M, Tsuzuki T, Ishikawa Y, Shirakami T, Yoshimura M, Kiyosuke Y, et al. Specific expression of HSP27 in human tumor cell lines in vitro. In Vivo. 1997;11:179–184
  49. Hannon GJ. RNA interference. Nature. 2002;418:244–251
  50. Dong W, Jin GH, Li SF, Sun QM, Ma DY, Hua ZC. Cross-linked polyethylenimine as potential DNA vector for gene delivery with high efficiency and low cytotoxicity. Acta Biochim. Biophys. Sin. (Shanghai). 2006;38:780–787
  51. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 2008;7:851–861
  52. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum. Gene Ther. 2007;18:39–50
  53. Jin CY, Moon DO, Lee JD, Heo MS, Choi YH, Lee CM, et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis. 2007;28:1058–1066
  54. Li S, Dong W, Zong Y, Yin W, Jin G, Hu Q, et al. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol. Ther. 2007;15:515–523
  55. Qian F, Li YP, Sheng X, Zhang ZC, Song R, Dong W, et al. PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol. Med. 2007;13:151–159
  56. Ozoren N, El Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003;13:135–147
  57. Ivanov VN, Hei TK. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp. Cell Res. 2006;312:4120–4138
  58. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW, et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 2003;94:1066–1073
  59. Peto R, Lopez AD, Boreham J, Thun M, Heath C, Doll R. Mortality from smoking worldwide. Br. Med. Bull. 1996;52:12–21
  60. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153–164
  61. Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta. 2004;1705:27–41
  62. Hao C, Song JH, Vilimanovich U, Kneteman NM. Modulation of TRAIL signaling complex. Vitam. Horm. 2004;67:81–99
  63. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer. 2001;1:142–150
  64. Ma Y, Lakshmikanthan V, Lewis RW, Kumar MV. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 2006;5:170–178
  65. Panner A, Murray JC, Berger MS, Pieper RO. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res. 2007;67:9482–9489
  66. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. 2000;2:469–475
  67. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 as a negative regulator of cytochrome C release. Mol. Cell Biol. 2002;22:816–834
  68. Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin. Cancer Res. 1995;1:1603–1609
  69. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, et al. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997;17:113–123
  70. Aloy MT, Hadchity E, Bionda C, Diaz-Latoud C, Claude L, Rousson R, et al. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 2008;70:543–553
  71. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 2007;6:299–308
  72. Appasani K. RNA interference technology in drug validation and development: RNomics approach. Pharmacogenomics. 2004;5:19–23
  73. Nganvongpanit K, Muller H, Rings F, Gilles M, Jennen D, Holker M, et al. Targeted suppression of E-cadherin gene expression in bovine preimplantation embryo by RNA interference technology using double-stranded RNA. Mol. Reprod. Dev. 2006;73:153–163
  74. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 2002;11:1137–1151
  75. Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, et al. Heat shock protein 27 controls apoptosis by regulating Akt activation. J. Biol. Chem. 2003;278:27828–27835
  76. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, Chantome A, et al. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol. Cell Biol. 2003;23:5790–5802
  77. Certo M, Del GM, Nishino V, Wei M, Korsmeyer G, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–365
  78. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin. Oncol. 2006;33:449–456
  79. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006;124:601–613
  80. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998;161:2833–2840
  81. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell Res. 2008;314:1163–1176
  82. Gong B, Chen Q, Endlich B, Mazumder S, Almasan A. Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases. Cell Growth Differ. 1999;10:491–502
  83. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 1997;17:141–143

PII: S0169-5002(09)00266-9

doi: 10.1016/j.lungcan.2009.05.014

Lung Cancer
Volume 68, Issue 1 , Pages 27-38 , April 2010

Article Tools

* Image Usage & Resolution